Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival (OS) in untreated fit patients; humanized ant...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325625/ |